Bacillus coagulans CGI314 Strain Colonization Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions of Bacilli strains are not sufficiently efficient in recolonizing in vivo microbial ecosystems, necessitating the identification of strains with enhanced colonization abilities.
Innovation Solution
The use of a new Bacillus coagulans strain, CGI314, alone or in combination with other Bacilli strains like Bacillus megaterium and Bacillus clausii, which possess improved colonization properties and are suitable for use in probiotics, prebiotics, and symbiotics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceutical compositions of Bacilli strains are used, then the basic probiotic function is provided, but the colonization efficiency in vivo is insufficient
Solution Approach 1:
The patent applies parameter changes by selecting and characterizing specific Bacillus coagulans strains with optimized physiological parameters for enhanced colonization. The strain CGI314 was specifically selected based on its ability to survive gastrointestinal stress, adhere to mucosal membranes, and colonize the intestinal flora, thereby improving colonization efficiency and reolonization ability compared to conventional Bacillus compositions
Solution Approach 2:
The patent uses in vitro test systems as copies or models to predict in vivo colonization ability. By developing and validating laboratory-based assays that replicate key aspects of the human gastrointestinal environment, the patent can screen and select strains with enhanced colonization properties without requiring extensive in vivo testing, thus improving identification efficiency
2Object-generated harmful factors
If Bacillus strains are administered to treat gastrointestinal infections, then antimicrobial activity is provided, but the ability to recolonize the microbial ecosystem is insufficient
Solution Approach 1:
The patent selects Bacillus coagulans strains with specific physiological parameters that enable both antimicrobial activity and effective recolonization. The strain CGI314 was characterized for its ability to produce antimicrobial substances while simultaneously colonizing the intestinal flora, thereby resolving the contradiction between harmful factor elimination and ecosystem restoration
Solution Approach 2:
The patent creates a composite functional profile by combining strains with multiple beneficial properties. The formulation includes Bacillus coagulans CGI314 in combination with other Bacillus strains (such as B. megaterium and B. clausii), creating a synergistic mixture that provides both antimicrobial activity against pathogens and effective recolonization of the microbial ecosystem
3Reliability
If strain identification processes are performed to find Bacilli with enhanced colonization abilities, then colonization efficiency is improved, but the process becomes cumbersome and time-consuming
Solution Approach 1:
The patent develops in vitro test systems that serve as simplified copies or models of the in vivo colonization process. These laboratory-based assays replicate key aspects of gastrointestinal survival and adhesion, allowing rapid screening of Bacillus strains for colonization ability without requiring lengthy in vivo studies, thus reducing the time needed for strain identification while maintaining reliability
Solution Approach 2:
The patent performs preliminary characterization and selection of Bacillus strains in the laboratory before clinical application. By pre-screening strains for colonization ability, survival under gastrointestinal stress, and antimicrobial activity using controlled in vitro conditions, the patent identifies promising candidates early in the process, reducing the overall time required for strain identification and formulation development
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described Bacillus coagulans strain CGI314 and its combinations effectively colonize mucosal membranes, providing antimicrobial, anti-inflammatory, and immunoprotective benefits, thereby treating or preventing various infections and diseases.
Implementation Method 1
Bacilli have been shown to possess inhibitory activity toward the growth of pathogenic bacteria such as Listeria monocytogenes, Escherichia coli, Salmonella spp. and others (Yilmaz et al., 2005). This inhibition could be due to the production of inhibitory compounds such as organic acids, hydrogen peroxide, bacteriocins or reuterin
Implementation Method 2
The strain shows bile stability. The strain shows acid stability. The strain show heat tolerance. The strain produces a natural antibiotic substance in the form of a bacteriocin.
Data Source
AI summary
The invention is directed to new Bacillus coagulans strain, which alone or in combination with other Bacilli strains can be used as probiotics or together with a prebiotic and a symbiotic. The invention also relates to a composition such as a pharmaceutical composition, dairy product, functional food, nutraceutical, dietary supplement, and product for personal care comprising the new Bacillus coagulans strain alone or in combination with other strains, as well as use of the strain for prevention or treatment gastrointestinal infections and diseases, and other uses.